Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 25 April 1997:
Vol. 276. no. 5312, pp. 520 - 523
DOI: 10.1126/science.276.5312.520
Prev | Table of Contents | Next

News & Comment

Jon Cohen

The advent of potent combination-drug therapies that can drive HIV in the blood to undetectable levels has thrown the world of AIDS drug testing into turmoil. Some researchers are lambasting drug developers for continuing to offer drug trial participants less than these optimal regimens. But there is hot debate about what constitutes "suboptimal" treatment. And some researchers also argue that to know how to maximize patients' options, clinical trials must examine a wide range of treatments, including those that may have only modest firepower against the virus. A Policy Forum on this topic appears on page 548.

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Some statistical issues in the design of HIV-1 vaccine and treatment trials.
P. B Gilbert (2000)
Statistical Methods in Medical Research 9, 207-229
   Abstract »    PDF »
Guidelines for managing HIV infection.
K. M De Cock (1997)
BMJ 315, 1-2
   Full Text »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)